Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
adenocarcinoma, advantage, antibody, augment, Biology, bladder, blockade, cancel, colon, confer, conference, confounded, crossover, die, ductal, emission, EndolucinBeta, escalation, eventually, exert, forward, gemcitabine, gland, identification, immunohistochemistry, Immunology, immunosuppressive, independent, integrated, Isotope, ITM, Journal, meaningful, mesenchymal, mesothelioma, microenvironment, molecular, monoclonal, mouse, Munich, neck, nonclinical, nuclear, path, Pharmacology, predetermined, predominantly, proposal, radioisotope, radiosensitizer, radiotherapy, representation, reserved, resistance, salivary, sarcoma, screen, screened, SE, secondary, sequentially, Srl, stopping, synergize, syngeneic, throughput, TRT, unknown
Removed:
dedicated, exclusively, impacted
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view